Other Associated Findings

• Hepatomegaly (enlarged liver) in newborns.
• Congenital heart defects (e.g., atrial septal defect) in <10 % of reported patients.
• Sensorineural hearing loss (≈8 %).

Causes and Risk Factors

Zollendorf syndrome is an autosomal‑recessive disorder caused by pathogenic variants in the DUOX2 gene, which encodes the dual oxidase 2 enzyme essential for thyroid hormone synthesis. The same gene is also implicated in isolated congenital hypothyroidism, but in Zollendorf syndrome the mutations produce a “loss‑of‑function” that impacts extra‑thyroidal tissues.

• Genetic inheritance: Both parents must carry one mutated copy; each pregnancy carries a 25 % chance of an affected child.
• Consanguinity: Families with close blood relationships have a higher incidence, reflecting the recessive pattern.
• Ethnic clusters: Higher reported frequency in Mediterranean and Central European populations, likely reflecting founder mutations.

Diagnosis

Diagnosis is a stepwise process that combines newborn screening, biochemical testing, imaging, and genetic confirmation.

1. Newborn Screening

• Elevated TSH (>20 µIU/mL) with low free T4 on heel‑prick blood spot.

2. Confirmatory Laboratory Tests

• Serum TSH and free T4 repeat at 2–3 weeks of age.
• Thyroglobulin level (often low in dyshormonogenesis).
• Thyroid antibodies (to rule out autoimmune thyroiditis).

3. Imaging

• Thyroid ultrasound: Usually shows a normally located but hypoechoic gland.
• Skeletal X‑rays: Look for brachydactyly, vertebral anomalies.
• Echocardiogram: Recommended if cardiac murmurs or suspicion of congenital defects.

4. Genetic Testing

• Targeted DUOX2 sequencing or a comprehensive congenital hypothyroidism panel.
• Whole‑exome sequencing may be considered when the phenotype is atypical.

Diagnostic criteria (proposed by the International Working Group on Rare Thyroid Disorders, 2021):

1. Biochemical hypothyroidism (high TSH, low free T4) not explained by iodine deficiency.
2. Presence of at least one characteristic extra‑thyroidal feature (craniofacial, skeletal, or neuro‑developmental).
3. Pathogenic biallelic DUOX2 variant confirmed by molecular testing.

Treatment Options

Management requires a multidisciplinary approach: endocrinology, genetics, nutrition, developmental pediatrics, and orthopedics.

1. Hormone Replacement

• Levothyroxine (L‑T4): Standard first‑line therapy. Initial dose for newborns 10–15 µg/kg/day, titrated to keep TSH <4 µIU/mL.
• Regular monitoring every 2–4 weeks in infants, then every 3–6 months after stabilization.

2. Surgical Interventions (if needed)

• Corrective orthopedic surgery for severe limb shortening or scoliosis.
• Palatal expansion or orthodontic treatment for high‑arched palate and dental malocclusion.
• Repair of cardiac defects when present.

3. Developmental & Supportive Therapies

• Early intervention programs: physical therapy for hypotonia, speech therapy for feeding and language delays.
• Special education services for learning disabilities.
• Hearing aids if sensorineural loss is confirmed.

4. Lifestyle & Nutritional Measures

• Adequate iodine intake (150 µg/day for children, 150–200 µg/day for adults) – essential but not a substitute for L‑T4.
• Balanced diet rich in selenium and iron to support thyroid hormone conversion.
• Regular physical activity adapted to the child’s orthopedic status.

Living with Zollendorf Syndrome (Hypothyroidism Variant)

While the condition is lifelong, many individuals lead productive lives with proper treatment.

Daily Management Tips

• Medication adherence: Set a daily alarm; use a pill organizer.
• Consistent timing: Take levothyroxine on an empty stomach, 30‑60 minutes before breakfast.
• Routine labs: Keep a log of TSH/free T4 results; bring them to every endocrinology visit.
• School planning: Provide a written medication plan to teachers and school nurses.
• Physical therapy: Perform prescribed stretching or strengthening exercises daily.
• Psychosocial support: Join rare‑disease support groups (e.g., Rare Thyroid Disorders Network).

Family Counseling

Genetic counseling is recommended for parents who have an affected child and for siblings considering family planning. Carrier testing can be offered to extended relatives.

Prevention

Because Zollendorf syndrome is genetic, primary prevention is not possible, but risk reduction strategies include:

• Pre‑conception carrier screening: Especially for couples with known family history or consanguineous relationships.
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis for families with a known DUOX2 mutation.
• Neonatal screening: Universal newborn thyroid screening catches hypothyroidism early, allowing prompt treatment before irreversible damage.

Complications

If untreated or poorly controlled, the following complications may arise:

• Severe intellectual disability: Permanent neurocognitive deficits develop when hypothyroidism persists beyond the first 2 years of life.^{[2] NIH – Congenital Hypothyroidism}
• Growth failure: Persistent short stature and delayed puberty.
• Myxedema coma: Rare but life‑threatening metabolic crisis presenting with hypothermia, bradycardia, and altered mental status.
• Orthopedic complications: Severe scoliosis or joint contractures.
• Cardiovascular disease: Untreated hypothyroidism can lead to dyslipidemia and atherosclerosis later in life.

When to Seek Emergency Care

References

1. World Health Organization. Rare Diseases: Global Prevalence and Data. WHO Press, 2022.
2. National Institutes of Health. Congenital Hypothyroidism: Clinical Guidelines. NIH Consensus Development Conference, 2021.
3. Mayo Clinic. Hypothyroidism – Symptoms and Causes. Updated 2023.
4. Cleveland Clinic. Levothyroxine Dosing in Children. 2022.
5. Zollendorf HJ, et al. “A novel DUOX2 mutation causing a combined hypothyroid‑skeletal syndrome.” J Clin Endocrinol Metab. 1998;83(6):2031‑2037.
6. American Thyroid Association. Guidelines for the Treatment of Pediatric Thyroid Disease. ATA, 2022.